Clinical Characteristics and Treatment Patterns of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Mexico

Speaker(s)

Flores- Caballero MA1, Lugo-Martinez G2, Rodríguez-Cid JR3, Juarez-Vignon Whaley J4, Martínez-Herrera JF5, Cruz-Zermeño M6, Seidman-Sorsby A6, García-Montes V7, Garibay-Diaz JC8, González Espinosa I8, Hernandez-Flores O9, Oyervides-Juarez VM10, López López F11, Gonzalez-Cisneros P12, Riera Sala R13, Alatorre-Alexander J3, Dorokhova E1, Betancur MA14, Medina S15, Flores-García L1, Amaya-Gutierrez MJ15, Rodriguez-Rosales Y1
1Merck Sharp &Dohme , México, cdmx, Mexico, 2Merck Sharp &Dohme , México, cdmx, MEX, Mexico, 3Instituto Nacional de Enfermedades Respiratorias, Mexico, DF, Mexico, 4Instituto Nacional de Enfermedades Respiratorias, Brookline, MA, USA, 5Centro Médico ABC, Mexico, DF, Mexico, 6Universidad Panamericana, Mexico, DF, Mexico, 7Hospital Español de Mexico, mexico, Mexico, 8Hospital MAC, Puebla, PU, Mexico, 9Oncologia Integral, Mexico, EM, Mexico, 10-Universidad Autónoma de Nuevo León, University Hospital “Dr. Jose Eleuterio Gonzalez”, Monterrey, NL, Mexico, 11San Peregrino Cancer center, aguas calientes, AG, Mexico, 12Hospital Angeles, San Luis Potosí, SL, Mexico, 13Instituto Nacional de Enfermedades Respiratorias, VERGEL DE ARBOLEDAS, MEX, Mexico, 14msd, bogota, bogota, Colombia, 15MSD, Bogotá, Bogotá, Colombia

Presentation Documents

OBJECTIVES: the aim of this study was to assess clinical characteristics of patients with metastatic Non-Small Cell Lung Cancer (mNSCLC) and their treatment patterns in Mexico

METHODS: This was a retrospective data-based study with data gathered from the SMEO (Mexican Society of Clinical Oncology) database between January 01,2016 and December 31, 2019 of patients with mNSCLC. Measures of central tendency and dispersion are presented for quantitative variables and frequencies for qualitative variables.

RESULTS: A total of 554 records were analyzed, the mean age were 63.3 years old. For the M-NSCLC (N= 554, 100%), the primary classification was: Non squamous (N=504, 91%), Squamous (N=50, 9%), and for the tumor type: Adenocarcinoma (N=498, 90%), Epidermoid (N=50, 9%), Large cell carcinoma (N=6, 1%).

The variables of the smoking index were 34.4 and 17.3 in squamous and non-squamous groups, respectively, and asbestos by year were 21.6 and 9.9 in squamous and non-squamous groups respectively. EGFR testing was performed in 68% of patients, 34.6% were positive. The ALK test was evaluated in 36.8% of the patients and 4.3% were positives. In terms of lines of treatment, 79.4% of the total subjects received first-line treatment, 37% second-line treatment, and 15.9% received third-line treatment. In the first line setting, 59.3% received chemotherapy, 37.4% received anti-EGFR medication, and 1.2% received anti-ALK treatment. For the treatment combinations, 43.1% of patients received Paclitaxel+Carboplatin, 31.5% Gefitinib, and 9.3% pemetrexed + carboplatin in squamous and non- squamous groups.

CONCLUSIONS: This is the first study in México about clinical features and treatment patterns, the most common histogy observed in mNSCLC was non squamous, adenocarcinoma was the most common tumor type, a higher smoking and asbestos index were observed in squamous histology, at the time of this analysis carboplatin and paclitaxel combinations is the most common first line treatment widely used in 40% of cases.

Code

EPH190

Topic

Clinical Outcomes

Topic Subcategory

Clinical Outcomes Assessment

Disease

Oncology